Lipoprotein(a): Resurrected by genetics

Journal of Internal Medicine

Volumn 273, Issue 1, 2013, Pages 6-30

  Kronenberg, F ^a   Utermann, G ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Apolipoprotein(a); Copy number variation; Coronary heart disease; Lipoprotein(a); Mendelian randomization; Quantitative genetic trait

Indexed keywords

APOLIPOPROTEIN B; ESTROGEN; GROWTH HORMONE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; THYROID HORMONE;

5' UNTRANSLATED REGION; ARTICLE; CATALYSIS; CHRONIC KIDNEY DISEASE; COPY NUMBER VARIATION; COVALENT BOND; DISULFIDE BOND; DNA STRUCTURE; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE MUTATION; GENE STRUCTURE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HETEROZYGOSITY; HETEROZYGOTE; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; LIVER CELL; LONG INTERSPERSED NUCLEAR ELEMENT; META ANALYSIS (TOPIC); METABOLIC RATE; NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; QUANTITATIVE TRAIT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW (TOPIC);

ALLELES; CORONARY ARTERY DISEASE; DNA; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIPOPROTEIN(A); MENDELIAN RANDOMIZATION ANALYSIS; POLYMORPHISM, GENETIC;

EID: 84871674237     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2012.02592.x     Document Type: Article

References (202)

1. Berg K. A new serum type system in man - the Lp system. Acta Path Microbiol Scand 1963; 59: 369-82.
2. Utermann G. The mysteries of lipoprotein(a). Science 1989; 246: 904-10.
3. Jauhiainen M, Koskinen P, Ehnholm C et al. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89: 59-67.
4. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993; 270: 2195-9.
5. Erqou S, Kaptoge S, Perry PL et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412-23.
6. Erqou S, Thompson A, Di AE et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58, 000 participants. J Am Coll Cardiol 2010; 55: 2160-7.
7. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301: 2331-9.
8. Trégouët DA, Konig IR, Erdmann J et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 2009; 41: 283-5.
9. Clarke R, Peden JF, Hopewell JC et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361: 2518-28.
10. Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844-53.
11. McLean JW, Tomlinson JE, Kuang W-J et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330: 132-7.
12. Lawn RM, Schwartz K, Patthy L. Convergent evolution of apolipoprotein(a) in primates and hedgehog. Proc Natl Acad Sci USA 1997; 94: 11992-7.
13. Tomlinson JE, McLean JW, Lawn RM. Rhesus monkey apolipoprotein(a). Sequence, evolution, and sites of synthesis. J Biol Chem 1989; 264: 5957-65.
14. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 1991; 87: 2153-61.
15. Kraft HG, Köchl S, Menzel HJ, Sandholzer C, Utermann G. The apolipoprotein(a) gene: a transcribed hypervariable locus controlling plasma lipoprotein(a) concentration. Hum Genet 1992; 90: 220-30.
16. Erdel M, Hubalek M, Lingenhel A, Kofler K, Duba HC, Utermann G. Counting the repetitive kringle-IV repeats in the gene encoding human apolipoprotein(a) by fibre-FISH [letter]. Nat Genet 1999; 21: 357-8.
17. Koschinsky ML, Beisiegel U, Henne-Bruns D, Eaton DL, Lawn RM. Apolipoprotein(a) size heterogeneity is related to variable number of repeat sequences in its mRNA. Biochemistry 1990; 29: 640-4.
18. Mooser V, Mancini FP, Bopp S et al. Sequence polymorphisms in the apo(a) gene associated with specific levels of Lp(a) in plasma. Hum Mol Genet 1995; 4: 173-81.
19. Huby T, Dachet C, Lawn RM, Wickings J, Chapman MJ, Thillet J. Functional analysis of the chimpanzee and human apo(a) promoter sequences: identification of sequence variations responsible for elevated transcriptional activity in chimpanzee. J Biol Chem 2001; 276: 22209-14.
20. Doucet C, Huby T, Chapman J, Thillet J. Lipoprotein[a] in the chimpanzee - relationship of Apo[a] phenotype to elevated plasma Lp[a] levels. J Lipid Res 1994; 35: 263-70.
21. Utermann G. Lipoprotein(a). In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2000; 2753-87.
22. Chennamsetty I, Claudel T, Kostner KM, Trauner M, Kostner GM. FGF19 signaling cascade suppresses APOA gene expression. Arterioscler Thromb Vasc Biol 2012; 32: 1220-7.
23. Chennamsetty I, Claudel T, Kostner KM et al. Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Invest 2011; 121: 3724-34.
24. Kraft HG, Menzel HJ, Hoppichler F, Vogel W, Utermann G. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 1989; 83: 137-42.
25. Dieplinger H, Utermann G. The seventh myth of lipoprotein(a): where and how is it assembled? Curr Opin Lipidol 1999; 10: 275-83.
26. Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol 2004; 15: 167-74.
27. White AL, Lanford RE. Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. J Biol Chem 1994; 269: 28716-23.
28. Becker L, Nesheim ME, Koschinsky ML. Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation. Biochemistry 2006; 45: 9919-28.
29. White AL, Lanford RE. Biosynthesis and metabolism of lipoprotein(a). Curr Opin Lipidol 1995; 6: 75-80.
30. Hobbs HH, White AL. Lipoprotein(a): intrigues and insights. Curr Opin Lipidol 1999; 10: 225-36.
31. Brunner C, Lobentanz EM, Pethö-Schramm A et al. The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells. J Biol Chem 1996; 271: 32403-10.
32. White AL, Guerra B, Lanford RE. Influence of allelic variation on apolipoprotein(a) folding in the endoplasmic reticulum. J Biol Chem 1997; 272: 5048-55.
33. White AL, Rainwater DL, Lanford RE. Intracellular maturation of apolipoprotein[a] and assembly of lipoprotein[a] in primary baboon hepatocytes. J Lipid Res 1993; 34: 509-17.
34. Raal FJ, Santos RD, Blom DJ et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 998-1006.
35. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989; 80: 1313-9.
36. Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008; 5: 497-505.
37. Menzel H-J, Dieplinger H, Lackner C et al. Abetalipoproteinemia with an apoB-100-lipoprotein(a) glycoprotein complex in plasma: indication for an assembly defect. J Biol Chem 1990; 265: 981-6.
38. Krempler F, Kostner GM, Bolzano K, Sandhofer F. Turnover of lipoprotein(a) in man. J Clin Invest 1980; 65: 1483-90.
39. Rader DJ, Cain W, Ikewaki K et al. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994; 93: 2758-63.
40. Niemeier A, Willnow T, Dieplinger H et al. Identification of Megalin/gp330 as a receptor for lipoprotein(a) in vitro. Arterioscler Thromb Vasc Biol 1999; 19: 552-61.
41. Krempler F, Kostner GM, Roscher A, Haslauer F, Bolzano K, Sandhofer F. Studies on the role of specific cell surface receptors in the removal of lipoprotein(a) in man. J Clin Invest 1983; 71: 1431-41.
42. Hofer G, Steyrer E, Kostner GM, Hermetter A. LDL-mediated interaction of Lp[a] with HepG2 cells: a novel fluorescence microscopy approach. J Lipid Res 1997; 38: 2411-21.
43. Utermann G, Hoppichler F, Dieplinger H, Seed M, Thompson G, Boerwinkle E. Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci USA 1989; 86: 4171-4.
44. Kronenberg F, Trenkwalder E, Lingenhel A et al. Renovascular arteriovenous differences in Lp(a) plasma concentrations suggest removal of Lp(a) from the renal circulation. J Lipid Res 1997; 38: 1755-63.
45. Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest 1996; 98: 2414-24.
46. Kostner KM, Maurer G, Huber K et al. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol 1996; 16: 905-11.
47. Frischmann ME, Kronenberg F, Trenkwalder E et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int 2007; 71: 1036-43.
48. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis 1996; 27: 1-25.
49. Koschinsky ML. Novel insights into Lp(a) physiology and pathogenicity: more questions than answers? Cardiovasc Hematol Disord Drug Targets 2006; 6: 267-78.
50. Miles LA, Plow EF. Lp(a): an interloper into the fibrinolytic system. Thromb Haemost 1990; 63: 331-5.
51. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler Thromb Vasc Biol 2012; 32: 1732-41.
52. Helgadottir A, Gretarsdottir S, Thorleifsson G et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol 2012; 60: 722-9.
53. Kapetanopoulos A, Fresser F, Millonig G, Shaul Y, Baier G, Utermann G. Direct interaction of the extracellular matrix protein DANCE with apolipoprotein(a) mediated by the kringle IV-type 2 domain. Mol Genet Genomics 2002; 267: 440-6.
54. Köchl S, Fresser F, Lobentanz E, Baier G, Utermann G. Novel interaction of apolipoprotein(a) with β-2 glycoprotein I mediated by the kringle IV domain. Blood 1997; 90: 1482-9.
55. Brown MS, Goldstein JL. Plasma lipoproteins: teaching old dogmas new tricks. Nature 1987; 330: 113-4.
56. Cushing GL, Gaubatz JW, Nava ML et al. Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis 1989; 9: 593-603.
57. Rath M, Niendorf A, Reblin T, Dietel M, Krebber H-J, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989; 9: 579-92.
58. Reblin T, Meyer N, Labeur C, Henne-Bruns D, Beisiegel U. Extraction of lipoprotein(a), apo B, and apo E from fresh human arterial wall and atherosclerotic plaques. Atherosclerosis 1995; 113: 179-88.
59. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993; 260: 1655-8.
60. Jamieson DG, Usher DC, Rader DJ, Lavi E. Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels - A potential role for endothelial cells in lesion formation. Am J Pathol 1995; 147: 1567-74.
61. Umahara T, Uchihara T, Yamada S et al. Differential expression of oxidized/native lipoprotein(a) and plasminogen in human carotid and cerebral artery plaques. Atherosclerosis 2011; 215: 392-8.
62. Syrovets T, Thillet J, Chapman MJ, Simmet T. Lipoprotein(a) is a potent chemoattractant for human peripheral monocytes. Blood 1997; 90: 2027-36.
63. Poon M, Zhang X, Dunsky KG, Taubman MB, Harpel PC. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 1997; 96: 2514-9.
64. Klezovitch O, Edelstein C, Scanu AM. Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein (a): evidence for a critical involvement of elements in its C-terminal domain. J Biol Chem 2001; 276: 46864-9.
65. Callow MJ, Stoltzfus LJ, Lawn RM, Rubin EM. Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice. Proc Natl Acad Sci USA 1994; 91: 2130-4.
66. Linton MF, Farese RV, Chiesa G et al. Transgenic mice expressing high plasma concentrations of human Apolipoprotein B100 and lipoprotein(a). J Clin Invest 1993; 92: 3029-37.
67. Fan J, Araki M, Wu L et al. Assembly of lipoprotein (a) in transgenic rabbits expressing human apolipoprotein (a). Biochem Biophys Res Commun 1999; 255: 639-44.
68. Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistent to tissue plasminogen activator-mediated thrombolysis. Nat Med 1995; 1: 256-9.
69. Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 1992; 360: 670-2.
70. Mancini FP, Newland DL, Mooser V et al. Relative contributions of apolipoprotein(a) and apolipoprotein- B to the development of fatty lesions in the proximal aorta of mice. Arterioscler Thromb Vasc Biol 1995; 15: 1911-6.
71. Sanan DA, Newland DL, Tao R et al. Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a). Proc Natl Acad Sci USA 1998; 95: 4544-9.
72. Bergmark C, Dewan A, Orsoni A et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 2008; 49: 2230-9.
73. Edelstein C, Pfaffinger D, Hinman J et al. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem 2003; 278: 52841-7.
74. Tsimikas S, Brilakis ES, Miller ER et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353: 46-57.
75. Kiechl S, Willeit J, Mayr M et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity and 10-year cardiovascular outcomes: prospective results from the bruneck study. Arterioscler Thromb Vasc Biol 2007; 27: 1788-95.
76. Tsimikas S, Mallat Z, Talmud PJ et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol 2010; 56: 946-55.
77. Edelstein C, Pfaffinger D, Yang M, Hill JS, Scanu AM. Naturally occurring human plasminogen, like genetically related apolipoprotein(a), contains oxidized phosphatidylcholine adducts. Biochim Biophys Acta 2010; 1801: 738-45.
78. Salonen EM, Jauhiainen M, Zardi L, Vaheri A, Ehnholm C. Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. EMBO J 1989; 8: 4035-40.
79. Jauhiainen M, Metso J, Koskinen P, Ehnholm C. Characterization of the enzyme activity of human plasma lipoprotein (a) using synthetic peptide substrates. Biochem J 1991; 274: 491-6.
80. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90: 52-60.
81. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987; 80: 458-65.
82. Utermann G, Kraft HG, Menzel HJ, Hopferwieser T, Seitz C. Genetics of the quantitative Lp(a) lipoprotein trait. I. Relation of Lp(a) glycoprotein phenotypes to Lp(a) lipoprotein concentrations in plasma. Hum Genet 1988; 78: 41-6.
83. Utermann G, Duba C, Menzel HJ. Genetics of quantitative Lp(a) lipoprotein trait. II. Inheritance of Lp(a) glycoprotein phenotypes. Hum Genet 1988; 78: 47-50.
84. Boerwinkle E, Menzel HJ, Kraft HG, Utermann G. Genetics of the quantitative Lp(a) lipoprotein trait. III. Contribution of Lp(a) glycoprotein phenotypes to normal lipid variation. Hum Genet 1989; 82: 73-8.
85. Ogorelkova M, Gruber A, Utermann G. Molecular basis of congenital Lp(a) deficiency: a frequent apo(a) 'null' mutation in Caucasians. Hum Mol Genet 1999; 8: 2087-96.
86. Cobbaert C, Kesteloot H. Serum lipoprotein(a) levels in racially different populations. Am J Epidemiol 1992; 136: 441-9.
87. Utermann G. Genetic architecture and evolution of the lipoprotein(a) trait. Curr Opin Lipidol 1999; 10: 133-41.
88. Lamon-Fava S, Jimenez D, Christian JC et al. The NHLBI Twin Study: heritability of apolipoprotein A-I and B, and low density lipoprotein subclasses and concordance for lipoprotein(a). Atherosclerosis 1991; 91: 97-106.
89. Austin MA, Sandholzer C, Selby JV, Newman B, Krauss RM, Utermann G. Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes. Am J Hum Genet 1992; 51: 829-40.
90. Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993; 2: 933-40.
91. Scholz M, Kraft HG, Lingenhel A et al. Genetic control of lipoprotein(a) concentrations is different in Africans and Caucasians. Eur J Hum Genet 1999; 7: 169-78.
92. Schmidt K, Kraft HG, Parson W, Utermann G. Genetics of the Lp(a)/apo(a) system in an autochthonous Black African population from the Gabon. Eur J Hum Genet 2006; 14: 190-201.
93. Mooser V, Scheer D, Marcovina SM et al. The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans. Am J Hum Genet 1997; 61: 402-17.
94. Sandholzer C, Hallman DM, Saha N et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet 1991; 86: 607-14.
95. Kraft HG, Sandholzer C, Menzel HJ, Utermann G. Apolipoprotein(a) alleles determine lipoprotein(a) particle density and concentration in plasma. Arterioscler Thromb 1992; 12: 302-6.
96. Trommsdorff M, Köchl S, Lingenhel A et al. A pentanucleotide repeat polymorphism in the 5′ control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J Clin Invest 1995; 96: 150-7.
97. Puckey LH, Lawn RM, Knight BL. Polymorphisms in the apolipoprotein(a) gene and their relationship to allele size and plasma lipoprotein(a) concentration. Hum Mol Genet 1997; 6: 1099-107.
98. Ogorelkova M, Kraft HG, Ehnholm C, Utermann G. Single nucleotide polymorphisms in exons of the apo(a) kringles IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians. Hum Mol Genet 2001; 10: 815-24.
99. Lanktree MB, Anand SS, Yusuf S, Hegele RA. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Genet 2010; 3: 39-46.
100. Dumitrescu L, Glenn K, Brown-Gentry K et al. Variation in LPA is associated with Lp(a) levels in three populations from the Third National Health and Nutrition Examination Survey. PLoS One 2011; 6: e16604.
101. Chretie JP, Coresh J, Berthier-Schaad Y et al. Three single-nucleotide polymorphisms in LPA account for the majority of lipoprotein(A) level elevation in African Americans compared to European Americans. J Med Genet 2006; 43: 917-23.
102. Teslovich TM, Musunuru K, Smith AV et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466: 707-13.
103. Aulchenko YS, Ripatti S, Lindquist I et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 2009; 41: 47-55.
104. Heid IM, Boes E, Müller A et al. Genome-wide association analysis of high-density lipoprotein cholesterol in the population-based KORA Study sheds new light on intergenic regions. Circ Cardiovasc Genet 2008; 1: 10-20.
105. Broeckel U, Hengstenberg C, Mayer B et al. A comprehensive linkage analysis for myocardial infarction and its related risk factors. Nat Genet 2002; 30: 210-4.
106. Barlera S, Specchia C, Farrall M et al. Multiple QTL influence the serum Lp(a) concentration: a genome-wide linkage screen in the PROCARDIS study. Eur J Hum Genet 2007; 15: 221-7.
107. Lopez S, Buil A, Ordonez J et al. Genome-wide linkage analysis for identifying quantitative trait loci involved in the regulation of lipoprotein a (Lpa) levels. Eur J Hum Genet 2008; 16: 1372-9.
108. Melzer D, Perry JR, Hernandez D et al. A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet 2008; 4: e1000072.
109. Ober C, Nord AS, Thompson EE et al. Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q. J Lipid Res 2009; 50: 798-806.
110. Zabaneh D, Kumari M, Sandhu M et al. Meta analysis of candidate gene variants outside the LPA locus with Lp(a) plasma levels in 14, 500 participants of six White European cohorts. Atherosclerosis 2011; 217: 447-51.
111. Kivimaki M, Magnussen CG, Juonala M et al. Conventional and Mendelian randomization analyses suggest no association between lipoprotein(a) and early atherosclerosis: the Young Finns Study. Int J Epidemiol 2011; 40: 470-8.
112. Qi Q, Workalemahu T, Zhang C, Hu FB, Qi L. Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. Eur Heart J 2012; 33: 325-34.
113. Kraft HG, Lingenhel A, Pang RWC et al. Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and African populations: the distribution of null alleles is non-random. Eur J Hum Genet 1996; 4: 74-87.
114. Marcovina SM, Albers JJ, Wijsman E, Zhang ZH, Chapman NH, Kennedy H. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res 1996; 37: 2569-85.
115. Crawford DC, Peng Z, Cheng JF et al. LPA and PLG sequence variation and kringle IV-2 copy number in two populations. Hum Hered 2008; 66: 199-209.
116. Deo RC, Wilson JG, Xing C et al. Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a) levels in African Americans. PLoS One 2011; 6: e14581.
117. Anuurad E, Rubin J, Chiem A, Tracy RP, Pearson TA, Berglund L. High levels of inflammatory biomarkers are associated with increased allele-specific apolipoprotein(a) levels in African-Americans. J Clin Endocrinol Metab 2008; 93: 1482-8.
118. Williams-Blangero S, Rainwater DL. Variation in Lp(a) levels and apo(a) isoform frequencies in five baboon subspecies. Hum Biol 1991; 63: 65-76.
119. Kwan BCH, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 2007; 18: 1246-61.
120. Kronenberg F, Kuen E, Ritz E et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000; 11: 105-15.
121. Dieplinger H, Lackner C, Kronenberg F et al. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 1993; 91: 397-401.
122. Kronenberg F, König P, Neyer U et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6: 110-20.
123. Stenvinkel P, Heimbürger O, Tuck CH, Berglund L. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int 1998; 53: 1336-42.
124. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-58.
125. Wanner C, Rader D, Bartens W et al. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 1993; 119: 263-9.
126. Kronenberg F, Lingenhel A, Lhotta K et al. The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. Kidney Int 2004; 65: 606-12.
127. De Sain-vanderVelden MGM, Reijngoud DJ, Kaysen GA et al. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol 1998; 9: 1474-81.
128. Kronenberg F, König P, Lhotta K et al. Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb 1994; 14: 1399-404.
129. Kronenberg F, Lhotta K, König P, Margreiter R, Dieplinger H, Utermann G. Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation. Eur J Hum Genet 2003; 11: 693-9.
130. Kerschdorfer L, König P, Neyer U et al. Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. Atherosclerosis 1999; 144: 381-91.
131. Kronenberg F, Neyer U, Lhotta K et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 1999; 10: 1027-36.
132. Longenecker JC, Klag MJ, Marcovina SM et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 2005; 16: 1794-802.
133. Mooser V, Seabra MC, Abedin M, Landschulz KT, Marcovina S, Hobbs HH. Apolipoprotein(a) kringle 4-containing fragments in urine. Relationship to plasma levels of lipoprotein(a). J Clin Invest 1996; 97: 858-64.
134. Kostner KM, Clodi M, Bodlaj G et al. Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function. Eur J Clin Invest 1998; 28: 447-52.
135. Kronenberg F, Steinmetz A, Kostner GM, Dieplinger H. Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci 1996; 33: 495-543.
136. Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem 2010; 56: 1252-60.
137. Rainwater DL, Haffner SM. Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype. Arterioscler Thromb Vasc Biol 1998; 18: 1335-41.
138. Neele DM, de Wit EC, Princen HM. Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes. Diabetologia 1999; 42: 41-4.
139. Heinrich J, Sandkamp M, Kokott R, Schulte H, Assmann G. Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem 1991; 37: 1950-4.
140. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006; 8: 538-54.
141. Hemelaar M, Van der Mooren MJ, Rad M, Kluft C, Kenemans P. Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil Steril 2008; 90: 642-72.
142. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001; 75: 898-915.
143. Persson L, Henriksson P, Westerlund E, Hovatta O, Angelin B, Rudling M. Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women. Arterioscler Thromb Vasc Biol 2012; 32: 810-4.
144. Lind S, Rudling M, Ericsson S et al. Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans. Arterioscler Thromb Vasc Biol 2004; 24: 349-56.
145. Heald A, Kaushal K, Anderson S et al. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk. Gynecol Endocrinol 2005; 20: 176-82.
146. Gaeta G, Lanero S, Barra S et al. Sex hormones and lipoprotein(a) concentration. Expert Opin Investig Drugs 2011; 20: 221-38.
147. Berglund L, Carlström K, Stege R et al. Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males. J Clin Endocrinol Metab 1996; 81: 2633-7.
148. Haffner SM, Mykkanen L, Gruber KK, Rainwater DL, Laakso M. Lack of association between sex hormones and Lp(a) concentrations in American and Finnish men. Arterioscler Thromb 1994; 14: 19-24.
149. Pearce EN. Update in lipid alterations in subclinical hypothyroidism. J Clin Endocrinol Metab 2012; 97: 326-33.
150. Tzotzas T, Krassas GE, Konstantinidis T, Bougoulia M. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 2000; 10: 803-8.
151. Meier C, Staub JJ, Roth CB et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001; 86: 4860-6.
152. Engler H, Riesen WF. Effect of thyroid function on concentrations of lipoprotein(a). Clin Chem 1993; 39: 2466-9.
153. Klausen IC, Hegedüs L, Hansen PS, Nielsen FE, Gerdes LU, Faergeman O. Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with hyperthyroidism. Clin Investig 1995; 73: 41-6.
154. Hoppichler F, Sandholzer C, Moncayo R, Utermann G, Kraft HG. Thyroid hormone (fT4) reduces lipoprotein(a) plasma levels. Atherosclerosis 1995; 115: 65-71.
155. Angelin B, Rudling M. Lipid lowering with thyroid hormone and thyromimetics. Curr Opin Lipidol 2010; 21: 499-506.
156. Ladenson PW, Kristensen JD, Ridgway EC et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010; 362: 906-16.
157. Tancevski I, Wehinger A, Demetz E et al. The thyromimetic T-0681 protects from atherosclerosis. J Lipid Res 2009; 50: 938-44.
158. Tancevski I, Demetz E, Eller P et al. The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice. PLoS One 2010; 5: e8722.
159. Edén S, Wiklund O, Oscarsson J, Rosén T, Bengtsson B-Å. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb 1993; 13: 296-301.
160. Hansen PS, Kassem M, Brixen K, Klausen IC, Mosekilde L, Faergeman O. Effect of short-term treatment with recombinant human growth hormone on lipids and lipoproteins in women and men without growth hormone disturbances. Metabolism 1995; 44: 725-9.
161. Johannsson G, Oscarsson J, Rosén T et al. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults - Influence of gender and apo(a) and ApoE phenotypes. Arterioscler Thromb Vasc Biol 1995; 15: 2142-50.
162. Wildbrett J, Hanefeld M, Fucker K et al. Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin-like growth factor I. Exp Clin Endocrinol Diabetes 1997; 105: 331-5.
163. Trenkwalder E, Gruber A, König P, Dieplinger H, Kronenberg F. Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease. Kidney Int 1997; 52: 1685-92.
164. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 1995; 41: 246-55.
165. Marcovina SM, Albers JJ, Scanu AM et al. Use of a reference material proposed by the international federation of clinical chemistry and laboratory medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 2000; 46: 1956-67.
166. Kronenberg F, Lingenhel A, Lhotta K et al. Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? Kidney Int 2004; 66: 348-54.
167. Scanu AM, Hinman J. Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels. Lipids 2002; 37: 439-44.
168. Miltiadous G, Saougos V, Cariolou M, Elisaf MS. Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia. Ann Clin Lab Sci 2006; 36: 353-5.
169. Deshmukh HA, Colhoun HM, Johnson T et al. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J Lipid Res 2012; 53: 1000-11.
170. Schunkert H, Konig IR, Kathiresan S et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011; 43: 333-8.
171. Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1986; 1: 507-8.
172. Seed M, Hoppichler F, Reaveley D et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990; 322: 1494-9.
173. Sandholzer C, Boerwinkle E, Saha N, Tong MC, Utermann G. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest 1992; 89: 1040-6.
174. Sandholzer C, Saha N, Kark JD et al. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb 1992; 12: 1214-26.
175. Kraft HG, Lingenhel A, Köchl S et al. Apolipoprotein(a) Kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 1996; 16: 713-9.
176. Li Y, Luke MM, Shiffman D, Devlin JJ. Genetic variants in the apolipoprotein(a) gene and coronary heart disease. Circ Cardiovasc Genet 2011; 4: 565-73.
177. Lin J-P, Schwaiger JP, Cupples LA et al. Conditional linkage and genome-wide association studies identify UGT1A1 as major gene for anti-atherogenic serum bilirubin levels - a Framingham Heart Study. Atherosclerosis 2009; 206: 228-33.
178. Luke MM, Kane JP, Liu DM et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 2007; 27: 2030-6.
179. Chasman DI, Shiffman D, Zee RY et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 2009; 203: 371-6.
180. Shiffman D, Chasman DI, Ballantyne CM, Nambi V, Devlin JJ, Boerwinkle E. Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost 2009; 102: 179-80.
181. Paultre F, Pearson TA, Weil HF et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and White men. Arterioscler Thromb Vasc Biol 2000; 20: 2619-24.
182. Moliterno DJ, Jokinen EV, Miserez AR et al. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vasc Biol 1995; 15: 850-5.
183. Virani SS, Brautbar A, Davis BC et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2012; 125: 241-9.
184. Geethanjali FS, Luthra K, Lingenhel A et al. Analysis of the apo(a) size polymorphism in Asian Indian populations: association with Lp(a) concentration and coronary heart disease. Atherosclerosis 2003; 169: 121-30.
185. Guerra R, Yu Z, Marcovina S, Peshock R, Cohen JC, Hobbs HH. Lipoprotein(a) and apolipoprotein(a) isoforms. No association with coronary artery calcification in the dallas heart study. Circulation 2005; 111: 1471-9.
186. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
187. Lingenhel A, Kraft H-G, Kotze M et al. Concentrations of the atherogenic Lp(a) are elevated in FH. Eur J Hum Genet 1998; 6: 50-60.
188. Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann G. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 522-8.
189. Rader DJ, Mann WA, Cain W et al. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995; 95: 1403-8.
190. Van der Hoek YY, Lingenhel A, Kraft HG, Defesche JC, Kastelein JJP, Utermann G. Sib-pair analysis detects elevated Lp(a) levels and large variation of Lp(a) concentration in subjects with familiar defective ApoB. J Clin Invest 1997; 99: 2269-73.
191. Friedlander Y, Leitersdorf E. Segregation analysis of plasma lipoprotein(a) levels in pedigrees with molecularly defined familial hypercholesterolemia. Genet Epidemiol 1995; 12: 129-43.
192. Wiklund O, Angelin B, Olofsson S-O et al. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet 1990; 335: 1360-3.
193. Holmes DT, Schick BA, Humphries KH, Frohlich J. Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem 2005; 51: 2067-73.
194. Jansen AC, van Aalst-Cohen ES, Tanck MW et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004; 256: 482-90.
195. Benn M. Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. Atherosclerosis 2009; 206: 17-30.
196. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005; 258: 94-114.
197. Lanford RE, Estlack L, White AL. Neomycin inhibits secretion of apolipoprotein[a] by increasing retention on the hepatocyte cell surface. J Lipid Res 1996; 37: 2055-64.
198. Chennamsetty I, Kostner KM, Claudel T et al. Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice. J Lipid Res 2012; doi: 10.1194/jlr.M029769 (in press).
199. Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67.
200. Cannon CP, Shah S, Dansky HM et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363: 2406-15.
201. Jaeger BR, Richter Y, Nagel D et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009; 6: 229-39.
202. Thompson GR. Lipoprotein apheresis. Curr Opin Lipidol 2010; 21: 487-91.